July 24, 2025

Perioperative Therapy With Durvalumab Plus FLOT: A Potential New Standard of Care in Gastric or Gastroesophageal Junction Cancer

In patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma, perioperative treatment with the checkpoint inhibitor durvalumab in combination with standard chemotherapy signif...

The ASCO Post

September 26, 2023

Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma

Discover the latest insights into sarcoma and rare adult solid cancers from the recent ESMO Sarcoma and Rare Cancers Congress, underlining the significance of multidisciplinary approaches and research efforts. Voices from young oncologists shed light on the pressing need for qualified resources. #ESMO2023

The ASCO Post

June 19, 2023

Aromatase Inhibitors May Limit Effectiveness of Weight Loss Medications in Breast Cancer Survivors

Aromatase inhibitors may interfere with the efficacy of weight loss medications in breast cancer survivors, according to a new study presented by Fansa et al at the 2023 Endocrine Society Annual Meeti...

The ASCO Post

October 04, 2023

Using Recent Diagnostic Scans May Cut Time to Treatment for Patients Needing Urgent Palliative Radiotherapy

Using previously taken diagnostic CT scans in place of CT simulation scans to plan simple palliative radiation treatments may substantially reduce the time spent waiting for urgent treatment, improvin...

The ASCO Post

March 12, 2025

Moderate-to-Vigorous Physical Activity May Lower Risk of Cardiovascular Disease–Related Mortality in Women With a Cancer History

Taking more daily steps and engaging in moderate-to-vigorous physical activity may both be associated with a reduced risk of cardiovascular disease–related mortality among postmenopausal women with a ...

The ASCO Post

May 30, 2025

Immune Checkpoint Inhibitors ‘High-Risk Yet Promising’ for Cancer Patients Who Undergo Organ Transplant

A meta-analysis led by a researcher at Roswell Park Comprehensive Cancer Center has identified key factors that could improve outcomes for cancer patients treated with immune checkpoint inhibitors (ICIs) before or after a solid-organ transplant.

Roswell Park Comprehensive Cancer Center

May 01, 2025

Join Roswell Park Experts for Our Quarterly Oncology Symposium May 7

Hear detailed case studies from experts in palliative care, surgical, medical and hematological oncology specializing in pancreatic cancer.

Roswell Park Comprehensive Cancer Center

February 12, 2025

Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem Meetings

Dana-Farber Cancer Institute researchers presented key research studies at the 2025 Tandem Meetings, the premier conference in hematopoietic cell transplantation (HCT) and cellular therapy.

Dana-Farber

March 25, 2025

2023-2024 Drug Updates: Investigational Therapeutics in the Pipeline

Explore the future of oncology with Vincent Harris, PharmD, as he unveils promising investigational therapies that may redefine treatment strategies for hematologic malignancies and solid tumors.

JADPRO